Audentes Therapeutics Aktie
WKN DE: A2ANZC / ISIN: US05070R1041
03.02.2025 16:38:34
|
Boundless Bio Appoints Robert Doebele As Chief Medical Officer
(RTTNews) - Boundless Bio Inc. (BOLD), a San Diego-based clinical-stage oncology company, Monday announced the appointment of Robert Doebele as Chief Medical Officer.
The company has been advancing its BBI-355 Phase 1/2 POTENTIATE trial and prepares to select a development candidate for its Kinesin program.
Doebele brings extensive experience in precision oncology, having co-founded Rain Oncology, Inc., where he had previously served as Chief Scientific and Medical Officer.
BOLD is currently trading at $2.31 up 0.87 percent or $0.02 on the Nasdaq.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Audentes Therapeutics Incmehr Nachrichten
Keine Nachrichten verfügbar. |